However, there exists an epidemiological correlation between patients having the same HLA-haplotypes that are known to bind the BCR-ABL peptides, such as HLA-A3, HLA-B8, and HLA-DR4, and resistance to developing CML [19-21]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.